Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PNMT | P11086 | 2/20 | 0.36 |
| ▸ | NR3C2 | P08235 | 2/20 | 0.34 |
| ▸ | HTR2A | P28223 | 2/20 | 0.33 |
| ▸ | HTR2C | P28335 | 2/20 | 0.33 |
| ▸ | HTR2B | P41595 | 2/20 | 0.33 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.33 |
| ▸ | HRH1 | P35367 | 1/20 | 0.33 |
| ▸ | S1PR3 | Q99500 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23843301 | 0.83 | NR3C2 (0.34) | NR3C2CYP2D6HRH1 | |
| SCHEMBL19346224 | 0.80 | TRPM8 (0.36) | NR3C2HTR2AHTR2CHTR2B | |
| SCHEMBL19227962 | 0.75 | NR3C2 (0.56) | NR3C2HTR2AHTR2CHTR2B | |
| SCHEMBL25744955 | 0.74 | HTR2A (0.33) | PNMTNR3C2HTR2AHTR2CHTR2B | |
| SCHEMBL12120626 | 0.73 | GABRA1 (0.40) | PNMTNR3C2HTR2AHTR2CHTR2B | |
| SCHEMBL20694181 | 0.73 | NR3C2 (0.42) | NR3C2CYP2D6 | |
| SCHEMBL1690313 | 0.73 | CYP2D6 (0.40) | PNMTCYP2D6HRH1S1PR3 | |
| SCHEMBL23982943 | 0.72 | CYP2D6 (0.39) | PNMTHTR2AHTR2CHTR2BCYP2D6 | |
| SCHEMBL22844051 | 0.72 | NR3C2 (0.43) | NR3C2HTR2AHTR2CHTR2B | |
| SCHEMBL22639289 | 0.71 | ESR1 (0.36) | NR3C2CYP2D6HRH1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10829485-B2 | ATF6 inhibitors and uses thereof | BLACK BELT TX LTD (GB) | 2020-11-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10829485-B2 | ATF6 inhibitors and uses thereof | ATF4, XBP1, ATF1 | PNMT 3274/4885NR3C2 1808/4885HTR2A 4707/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.